From Biospecimen to Biomarker: Evolving Lung Cancer Care With ctDNA Innovations Beyond Genotyping

Circulating tumour DNA (ctDNA) is a recognised biospecimen for genotyping in advanced non-small cell lung cancer (NSCLC). Its emerging utility includes serving as a biomarker for prognostication and treatment monitoring for the settings of advanced and early-stage disease. This presentation will cover the biology of DNA shedding to measure disease burden before and after treatment. It will discuss the rationale for the long-term goal of incorporating ctDNA status into NSCLC staging and real-time treatment monitoring. Outlining latest data and evidence gaps, while also addressing steps for translating these advancements into clinical practice during the Q&A session.